Key facts
- This page summarizes Barry D. Quart's Form 4 filing for Kiniksa Pharmaceuticals, Ltd. (KNSA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jul 2023, 16:15.
Barry D. Quart - 29 Jun 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)
- Reporting relationship
- Director
- Issuer ticker
- KNSA
- Reported as of
- 29 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jul 2023, 16:15:04 UTC
- Prior SEC filing
- 08 Jun 2023
- Next SEC filing
- 07 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Madelyn Zeylikman, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Barry D. Quart filed Form 4 for Kiniksa Pharmaceuticals, Ltd. (KNSA) on 03 Jul 2023.
Change
- Previous filing in this sequence was filed on 08 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KNSA
transaction
Class A Common Share
Options Exercise
- Transaction value
- Shares
- +5,000
- Change %
- Price
- Shares after
- 5,000
- Date
- 29 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KNSA
transaction
Derivative
Restricted Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 29 Jun 2023
- Ownership
- Direct
- Underlying class
- Class A Common Shares
- Underlying amount
- 5,000
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
Footnote F2
The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.